Logo image of DXR

DAXOR CORP (DXR) Stock Fundamental Analysis

USA - NASDAQ:DXR - US2394671034 - Common Stock

13 USD
+0.3 (+2.36%)
Last: 10/16/2025, 8:00:01 PM
Fundamental Rating

3

Overall DXR gets a fundamental rating of 3 out of 10. We evaluated DXR against 191 industry peers in the Health Care Equipment & Supplies industry. The financial health of DXR is average, but there are quite some concerns on its profitability. DXR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year DXR was profitable.
DXR had a positive operating cash flow in the past year.
DXR had positive earnings in 4 of the past 5 years.
DXR had negative operating cash flow in 4 of the past 5 years.
DXR Yearly Net Income VS EBIT VS OCF VS FCFDXR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M

1.2 Ratios

DXR has a better Return On Assets (5.01%) than 82.20% of its industry peers.
DXR has a better Return On Equity (5.05%) than 78.53% of its industry peers.
Industry RankSector Rank
ROA 5.01%
ROE 5.05%
ROIC N/A
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
DXR Yearly ROA, ROE, ROICDXR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

DXR's Profit Margin of 2707.08% is amongst the best of the industry. DXR outperforms 99.48% of its industry peers.
DXR's Profit Margin has declined in the last couple of years.
DXR does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 2707.08%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DXR Yearly Profit, Operating, Gross MarginsDXR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for DXR has been increased compared to 1 year ago.
DXR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for DXR has been reduced compared to a year ago.
DXR Yearly Shares OutstandingDXR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
DXR Yearly Total Debt VS Total AssetsDXR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

An Altman-Z score of 143.44 indicates that DXR is not in any danger for bankruptcy at the moment.
DXR has a better Altman-Z score (143.44) than 100.00% of its industry peers.
The Debt to FCF ratio of DXR is 0.19, which is an excellent value as it means it would take DXR, only 0.19 years of fcf income to pay off all of its debts.
DXR has a better Debt to FCF ratio (0.19) than 93.72% of its industry peers.
DXR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.01, DXR is doing good in the industry, outperforming 72.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.19
Altman-Z 143.44
ROIC/WACCN/A
WACCN/A
DXR Yearly LT Debt VS Equity VS FCFDXR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

DXR has a Current Ratio of 0.04. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of DXR (0.04) is worse than 97.91% of its industry peers.
DXR has a Quick Ratio of 0.04. This is a bad value and indicates that DXR is not financially healthy enough and could expect problems in meeting its short term obligations.
DXR has a worse Quick ratio (0.04) than 97.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.04
Quick Ratio 0.04
DXR Yearly Current Assets VS Current LiabilitesDXR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

DXR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.97%, which is quite impressive.
DXR shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -54.84% yearly.
DXR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -56.97%.
DXR shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -20.63% yearly.
EPS 1Y (TTM)20.97%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%77.93%
Revenue 1Y (TTM)-56.97%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-74.37%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DXR Yearly Revenue VS EstimatesDXR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M
DXR Yearly EPS VS EstimatesDXR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 0.02 0.04 0.06 0.08

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 31.71, DXR can be considered very expensive at the moment.
DXR's Price/Earnings ratio is a bit cheaper when compared to the industry. DXR is cheaper than 72.25% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.31, DXR is valued at the same level.
Industry RankSector Rank
PE 31.71
Fwd PE N/A
DXR Price Earnings VS Forward Price EarningsDXR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

76.44% of the companies in the same industry are more expensive than DXR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 46.69
EV/EBITDA N/A
DXR Per share dataDXR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DXR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DAXOR CORP

NASDAQ:DXR (10/16/2025, 8:00:01 PM)

13

+0.3 (+2.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)03-04 2026-03-04
Inst Owners2.01%
Inst Owner Change0%
Ins Owners5.42%
Ins Owner Change0%
Market Cap64.74M
Analysts80
Price Target23.97 (84.38%)
Short Float %1.15%
Short Ratio0.71
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 31.71
Fwd PE N/A
P/S 975
P/FCF 46.69
P/OCF 46.69
P/B 1.82
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)0.41
EY3.15%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.28
FCFY2.14%
OCF(TTM)0.28
OCFY2.14%
SpS0.01
BVpS7.15
TBVpS7.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.01%
ROE 5.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 2707.08%
GM N/A
FCFM 2088.4%
ROA(3y)6.45%
ROA(5y)5.61%
ROE(3y)6.73%
ROE(5y)6.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-35.84%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.19
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 77.15%
Current Ratio 0.04
Quick Ratio 0.04
Altman-Z 143.44
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.97%
EPS 3Y-54.84%
EPS 5YN/A
EPS Q2Q%77.93%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-56.97%
Revenue growth 3Y-24.67%
Revenue growth 5Y-20.63%
Sales Q2Q%-74.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-83.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y144.02%
FCF growth 3YN/A
FCF growth 5Y-61.68%
OCF growth 1Y144.02%
OCF growth 3YN/A
OCF growth 5Y-61.68%